Previous 10 | Next 10 |
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO ) investors concerning the Company and its officers’ possible violations of federal securi...
Here, I continue my coverage of the micro-cap oncology player AVEO Oncology ( AVEO ). In my previous piece , I discussed the issues AVEO encountered with the FDA regarding the results of the TIVO-1 trial, and how the FDA’s concerns may not be ameliorated by the available results of the...
CORAL GABLES, FL/ ACCESSWIRE / February 21, 2019 / The future of the biotech stock market is dependent on whether medical experts have the ability to continue pioneering advancements in medicine and other innovative solutions to curing diseases. The biotech industry is relatively new but s...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be...
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clin...
Noteworthy events during the week of February 10 - 16 for healthcare investors. More news on: Momenta Pharmaceuticals, Inc., Motif Bio, AVEO Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
On January 31st, AVEO Pharmaceuticals ( AVEO ) announced that it had recognized the recommendation by the FDA to not submit their FOTIVDA (tivozanib) NDA with the preliminary overall survival "OS" results from the Phase III TIVO-3 trial for the third-line treatment of adult patients with a...
The saddest life is that of a political aspirant under democracy. His failure is ignominious and his success is disgraceful. " - H.L. Mencken AVEO Pharmaceuticals ( AVEO ) was crushed in trading late last week. This is a name I have had several profitable Buy-Write positions expire over...
Gainers: Fortress Biotech (NASDAQ: FBIO ) +41% . MeiraGTx Holdings (NASDAQ: MGTX ) +29% . Eldorado Gold (NYSE: EGO ) +23% . Avon Products (NYSE: AVP ) +22% . Silicom (NASDAQ: SILC ) +20% . Onconova Therapeutics (NASDAQ: ONTX ) +20% . 1-800-FLOWERS.COM (NASDAQ: FLWS ) +19% . Tu...
AVEO Pharmaceuticals ( AVEO -45.8% ) slumps out of the gate this morning following its announcement that it will not file a U.S. marketing application seeking approval for FOTIVDA (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (kidney cancer) until it ...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...